Business Wire

TRUFFLE-CAPITAL

26.6.2020 09:12:07 CEST | Business Wire | Press release

Share
Truffle Capital and tecknowlogy Group Unveil the Results of the 15th "Truffle 100" Ranking

On the face of it, the "Truffle 100" 2020 has drawn the curtain on a decade of continuous growth, which has been abruptly halted by the Covid-19 pandemic:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200626005086/en/

  • Several records were set in 2019: cumulative turnover for the sector was €10.8bn, total workforce in the sector stood at 157,000 jobs including 25,000 in R&D. Profitability at 11.1 % is very close to its historical high of 2006-2007. Moreover, buybacks and stock market transactions were sharply higher.

Despite the fact that the solid foundations built over the last decade will be exposed to a brutal shock in 2020, the Truffle 100 clearly shows that the areas in which software publishers have invested the most extensively are those that will be the most vital to withstand the current crisis and support the economic recovery:

  • Thanks to their profit margins, which have returned to previous levels, software publishers have been able to ensure continuous research in crucial areas (in particular, the Cloud and artificial intelligence, which are the two major market trends) to support the transition to teleworking in the economy of tomorrow.

While 62% of software publishers forecast a downturn in 2020, 94% expect a return to growth in 2021.

Commenting on the 15th edition of the "Truffle 100", Bernard-Louis Roques, General Manager and Co-founder of Truffle, declared: "Software is a digital business and software publishers have been among the quickest to adapt to the crisis. In just a few months, Covid-19 brought about a forced acceleration in terms of the company's digital transition, with an irreversible digitalization of uses and organizations. Publishers will play a vital role in the development of the "post-Covid world". Finally, I would like to thank Cédric Ô, the French Secretary of State for the Digital Economy, for agreeing to sponsor the 15th edition of the "Truffle 100", which is more than a just an overview of the past, it is a leading indicator of the future. "

Xavier Negiar, Chairman of the consulting and analysis firm teknowlogy Group which carried out the study and analysis, added:

"As grey as this picture may be, there has been a major trend in this software market to prepare for the end of the crisis. Now is the time to develop programs that are capable of reviving the market. And to achieve this, surely the best approach is to help companies find their own way out of this crisis. "

Cédric Ô, the French Secretary of State for the Digital Economy concluded:

"Software publishers are at the core of all these changes taking place in our societies. They act as stakeholders as well as sentinels and open up new pathways for improvement for the companies they support, the employees who use their solutions and for each and every citizen, which result in significant transformations to life and work. It is this key role that explains the economic strength and resilience of this strategic sector, which is central to France's entrepreneurial fabric and excellence.

The 15th edition of the "Truffle 100", as well as the previous editions, can be viewed on the following website: https://www.truffle100.fr/

About Truffle Capital

Founded in 2001, Truffle Capital is an independent European venture capital company, specializing in life sciences (BioTech and MedTech) and breakthrough technologies in the IT sectors (FinTech and InsurTech). Truffle Capital’s mission is to support the creation and development of young innovative companies capable of becoming tomorrow’s leaders. The company is chaired by Patrick Kron and managed by Dr Philippe Pouletty and Bernard-Louis Roques, co-founders and General Managers. Since its creation, Truffle Capital has raised nearly €1.1 billion and has supported over 70 companies in the digital technology and life sciences sectors. In 2019, Truffle Capital announced it had raised nearly €400 million in new institutional funds.

About teknowlogy Group

For more than 45 years, PAC and CXP have been providing visionary and meticulous support, helping stakeholders to grow and adapt in what has become today's IT ecosystem, as well as assisting companies seeking to accelerate their digitalization process. PAC's M&A teams serve the investment fund community both with regard to acquisitions and in the analysis of the coherence of the BP (Business Plan) of their holdings in view of market trends. PAC's teams of analysts also advise ESNs, software publishers and IT service providers in terms of deciphering technological needs to enable them to adapt their strategy to offer solutions and services, owing to their oversight of European and international markets. Thanks to SITSI®, its international platform for real-time monitoring, PAC maintains an up-to-date vision of technologies and markets, and provides its customers with strategic analyses and solution benchmarks for a 360° outlook of the IT market. CXP's Project Consulting teams support TIEs and SMEs in drafting specifications, identifying IT service providers, selecting and implementing solutions adapted to their digital transformation challenges. Thanks to the MyTeknow site - CXP's platform - users now have access to a real-time monitoring of the IT services on offer in France to TIEs and SMEs.

More information: www.truffle.com — Twitter: @trufflecapital

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release

~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye